Dexcom CGM helps patients with T2D make positive behavior

progress starts with a superior CGM

DEXCOM WAS PROVEN SUPERIOR IN IMPROVING OUTCOMES FOR ADULTS WITH T2D*,1,3,4


 

Dexcom makes a difference for T2D patients

patients with T2D on insulin may experience 
additional benefits compared to BGM

down arrow
additional weight loss 
vs. BGM alone†,1

 

insulin vial
decrease total daily 
dose of insulin1

 

patients using Dexcom CGM also reported:

 

1feeling more empowered and in control of their 
diabetes6

2less diabetes distress1

3higher diabetes treatment satisfaction
compared to BGM users1


3 Months

a separate clinical trial for T2D patients not on insulin showed: 

significant improvements in glucose and cardiovascular risk-
reduction measures as early as 3 months‡,§,7

 

easily check your patient's pharmacy coverage for Dexcom CGM

 COVERAGE EVALUATOR

T2D patients experience additional benefits with Dexcom G7 like:

Dexcom G7 Warrior Dan

no fingersticksno fingersticks from day 1!||

 

96%it's easy to use—according to 96% of patients8

 

get your patients

started for free today

PRESCRIBE & SAMPLE

more patients pay $0 for

Dexcom G7 compared to Libre¶,9

COVERAGE & AFFORDABILITY

BGM = blood glucose monitoring; CGM = continuous glucose monitoring; isCGM = intermittently scanned continuous glucose monitoring; T2D = type 2 diabetes; TAR = time above range; TBR = time below range.

*Comparing Dexcom CGM and BGM for patients with T2D on insulin. †Secondary outcome, not meeting power (P<0.05). Incretin and SGLT2 use was similar with CGM and BGM and likely contributed to weight loss outcomes at 12 months. ‡Results obtained from previous Dexcom device(s). §Cardiovascular risk refers to 10-year ASCVD risk. Visit https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/ to access the American College of Cardiology ASCVD Risk Estimator Plus. ||Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. ¶Individual pricing may vary depending on commercial insurance coverage.

1 Lind N, et al. Diabetes Care. 2024;47(5):881-889. 2 Ehrhardt N, et al. Clin Diabetes. 2020;38(2):126-131. 3 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 4 Martens T, et al. JAMA. 2021;325(22):2262-2272. 5 Grace TP, et al. Clin Diabetes. 2024;42(4):540-546. 6 Clark TL, et al. Diabetes Technol Ther. 2024;26(10):700-708. 7 Reed J, et al. Diabetes Obes Metab. 2024;26(7):2881-2889. 8 Dexcom G7 User Guide, 2024. 9 Dexcom, Data on File, 2024.

Contact Us

If you are a healthcare provider and want to learn more about Dexcom, please fill out the form and a representative will contact you. If you are a Dexcom User or Patient, please contact Dexcom here.

Contact Reason

Please note: To ensure a successful transaction, please provide information that matches the Provider’s medical license information. A valid business address is required for a request to be fulfilled.

Do not include prefix (Mr., Mrs., Dr.)
As listed on Provider’s medical license (no MD, Jr., Sr.)
Please use the Provider’s NPI
Please provide Facility/Office address Only- We will not ship to home address
Is your patient on a connected pump device?

 

By choosing to request info, you are granting Dexcom, Inc. permission to process your personal information to send you additional information and promotional communications related to Dexcom products. You may opt-out of these communications at any time. Dexcom respects the privacy and confidentiality of your personal information. The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.